Targeted therapies and immunotherapy can provide benefits when added to chemotherapy or may eliminate the need for ...

Adding nivolumab to neoadjuvant chemotherapy improved OS in patients with resectable NSCLC in the CheckMate 816 trial.

Both hand cooling and hand compression reduced the incidence of grade 2 or higher chemotherapy-induced peripheral neuropathy ...

Research presented at the ASCO Annual Meeting 2025 highlighted potential new standards of care and other advances in ...

A prognostic index can be used to identify patients with estrogen receptor (ER)-positive, HER2-negative early breast cancer who can safely forgo adjuvant chemotherapy as well as patients who require ...

Nivolumab plus chemotherapy significantly improved OS vs chemo alone in resectable NSCLC, per updated CheckMate-816 findings.

Studies presented at the ASCO Annual Meeting 2025 highlighted immunotherapies that may provide new standards of care for ...

The combination of toripalimab, nimotuzumab, and chemotherapy showed “promising antitumor activity with acceptable toxicity,” researchers wrote.

A large prospective study suggests pro-inflammatory diets may increase risk of death in patients with stage III colon cancer, ...

IMNN READ THE FULL IMNN RESEARCH REPORT Business Update OVATION 2 Translational Data Presented at ESMO On June 18, 2025, ...

Physical activity for cancer survivors supported by recent research; CAPABLE helps cancer survivors find their physical ...